GHRP-6 vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- 15–60 minutes
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 10 mg per day
- Frequency
- 2–3 times daily
- Daily for 10–30 days
- Key Benefits
- Strong GH stimulation
- Elevated IGF-1
- Muscle growth and recovery support
- Potential anti-inflammatory effects at GI level
- Useful for patients with appetite deficiency or cachexia
- Enhanced recovery from training
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Intense hunger surge (30–45 min post-injection)
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —